Health Care·Health Care Equipment·$92.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.32 | N/A | +2.84% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.32 | N/A | +2.84% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management remains positive about the company's direction despite some market challenges. They emphasized their commitment to innovation and growth.
Management highlighted ongoing product innovation as a key driver for future growth.
They acknowledged challenges in certain markets but expressed confidence in their long-term strategy.
Boston Scientific's earnings report shows a slight beat on EPS, indicating better-than-expected profitability. However, the stock fell by 1.35%, likely due to a lack of revenue data and no guidance updates, which may have left investors uncertain about future performance. The company's focus on innovation suggests potential for growth, but market challenges remain a concern.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 24, 2017